Advertisement Antisoma gets QTDP grant for AS1413 development - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Antisoma gets QTDP grant for AS1413 development

Antisoma, Inc, the US subsidiary of Antisoma, has received a grant of $244,000 under the US Government's Qualifying Therapeutic Discovery Project (QTDP), forits ongoing development of AS1413 (amonafide L-malate), a novel treatment for acute myeloid leukaemia (AML).

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer.

The company has operations in London, UK and Cambridge, MA.

Antisoma, Inc, Clinical Operations VP Chris Smyth said that they are pleased that the development of AS1413 has qualified for this recognition, and look forward to reporting the key phase III data on the drug in the near future.

QTDP grants are awarded to projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the US, or significantly advance the goal of curing cancer within 30 years.